• Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology

  • Jan 27 2025
  • Length: 6 mins
  • Podcast

Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology

Listen for free

View show details

  • Summary

  • Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties. Sona’s proprietary technology employs patented, biocompatible gold nanorods (GNRs) to deliver precision, non-invasive hyperthermia therapy directly to cancer cells. This approach minimizes systemic toxicity, a common drawback of traditional cancer treatments. The study demonstrated that Sona’s THT induces cancer-specific cell death while triggering a robust immune response, marking a significant breakthrough in cancer immunotherapy. Notably, the research revealed that the immune response activated by Sona’s THT is effective against cancers that are typically resistant to modern immunotherapies. This novel immunity offers a critical advantage, paving the way for new treatment possibilities in cases where conventional methods fall short. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #GoldNanorods #TargetedTherapy #Biotechnology #CancerTreatment #HyperthermiaTherapy #Immunology #MedicalBreakthroughs #Nanotechnology
    Show more Show less
Show more Show less

What listeners say about Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available